References
- Harris E N, Boey M L, Mackworth-Young C G, Gharavi A E, Patel B M, Loizou S, Hughes G RV. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in Systemic Lupus Erythematosus. Lancet 1983; ii: 1211–1214
- Loizou S, McCrea J D, Rudge A C, Reynolds R, Boyle C C, Harris E N. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738–745
- Alarcon Segovia D, Delete M, Oria C V, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, Fernandez L, Ponce De Leon S. Antiphospholipid antibodies and the antiphospholipid syndrome in Systemic Lupus Erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353–365
- Derksen R HWN, Kater L. Lupus Anticoagulant: revival of an old phenomenon. Clin Exp Rheumatol 1985; 3: 349–357
- Sammaritano L R, Gharavi A E, Lockshim M D. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arthritis Rheum 1990; 20: 81–96
- Hughes G RV, Asherson R A, Khamashta M A. Antiphospholipid syndrome: linking many specialties. Annals Rheum Dis 1989; 48: 355–356
- Meroni P L, Tincani A, Harris E N, Valesini G, Hughes G RV, Balestrieri G. The pathophysiology of anti-phospholipid antibodies. Clin Exp Rheumatol 1989; 7/S-3: 81–84
- Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069–3073
- Bakimer R, Fishman P, Blank M, Sredni B, Djaldelty M, Shoenfeld Y. Induction of Primary Antiphospholipid Syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558–1563
- McNeil H P, Hunt J E, Krilis S A. New aspects of anticardiolipin antibodies. Clin Exp Rheumatol 1990; 8: 525–527
- McNeil H P, Chesterman C N, Krilis S A. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipids binding characteristics. British Journ of Haematol 1989; 73: 506–513
- McNeil H P, Krilis S A, Chesterman C N. Purification of antiphospholipid antibodies using a new affinity method. Thrombosis Research 1988; 52: 641–648
- McNeil H P, Richard J S, Chesterman C N, Krilis S A. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-giyco-protein-I (apolipoprotein-H). Proc Natl Acad Sci USA 1990; 87: 4120–4124
- Galli M, Comfurios P, Maassen C, Hemker H C, De Baets M H, van Breda-Vriesman P JC, Barbui T, Zwaal R FA, Bevers E M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–47
- Harris N E, Pierangeli S. What is the “true” antigen for antiphospholipid antibodies?. Lancet 1990; 330: 1505
- Harris N E, Pierangeli S, Barquinero J, Ordi-Ros J. Anticardiolipin antibodies and binding of anionic phospholipids and serum protein. Lancer 1990; 336: 505–506
- McNeil H P. Specificity of antiphospholipid antibodies. September 25, 1991, Antiphospholipid antibodynupus Anticoagulant workshop. NIH Bethesda
- Shapiro S S, Thiagarajan P, Essex D, Love T. Studies on the specificity of anticardiolipin antibodies. September 25, 1991, Antiphospholipid antibody/Lupus Anticoagulant workshop. NIH Bethesda
- Tincani A. β2 GPI seric levels and antibodies against β2 GPI in patients with primary and secondary anti-phospholipid syndrome. International workshop on β2-GPI and antiphospholipid antibodies. Milano October 25–26, 1991
- Atkin J, Rundle A T. Serum β2-glycoprotein-I phenotype frequencies in an English population. Humangenetik 1974; 21: 81–84
- Cleve H. Genetic studies on the deficiency of β2-glycoprotein-I of human serum. Humangenetik 1968; 5: 294–304
- Cleve H, Rittner C. Further family studies on the genetic control of β2-glycoprotein-I concentration in human serum. Humangenetik 1969; 7: 93–97
- Propert D N. The relation of sex, smoking status, birth rank, and parental age to β2-glycoprotein-I levels and phenotypes in a sample of Australian Caucasian adults. Human Genet 1978; 43: 281–288
- Schousboe I. β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086–1091
- Nimpf J, Bevers E M, Bomans P HH, Till U, Wurm H, Kostner G M, Zwaal R FA. Protrombinase activity of human platelets is inhibited by β2-glycoprotein-I. Biochim et Eiophys Acta 1986; 884: 142–149
- Canfield W M, Kisiel W. Evidence of normal functional levels of activated protein C inhibitor in combined vector V/VIII deficiency disease. J Clin Invest 1982; 70: 1260–1272
- Nimpf J, Wurm H, Kostner G. β2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109–114
- Nimpf J, Bevers E M, Bomans P HH, Tii U., Wurm H, Kostner G M, Zwaal R FA. Protrombinase activity of human platelets is inhibited by β2-glycoprotein-I. Biochim et Eiophys Acta 1986; 884: 142–149
- Schousboe I. Binding of β2-glycoprotein-I to platelets: effects of adenylate cyclase activity. Thrombosis Research 1980; 19: 225–237
- Hoeg J M, Segal P, Gregg R E, Chang Y S, Lindgren F T, Adamson G L, Frank M, Brikman C, Brewer H B, Jr. Characterization of plasma lipids and lipoproteins in patients with β2-Glycoprotein I (Apolipoprotein H) deficiency. Artherosclerosis 1985; 55: 25–34
- McNeil H P. Anticardiolipin antibody-β2GPI interaction. International workshop on β2GPI and antiphospholipid antibodies. Milano October 25–26, 1991
- Shultze H E, Heide K, Haupt M. Uber ein bisher unbekanutes niedermolekulares β2-globulin des humanserums. Naturwissenshaften 1961; 48: 719–721
- Polz E, Wurm H, Kostner G M. Investigations on β2-glyco-protein-l in the rat; isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980; 11: 265–270
- Wurm H. β2-glycoprotein-I (Apoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511–515
- Lozier J, Takashashi N, Putnam F W. Complete amino acid sequence of human plasma β2-glycoprotein-I. Proc Natl Acad Sci USA 1984; 81: 3640–44
- Reid K BM, Day A J. Structure-function relationships of the complement components. Immunology Today 1989; 10: 177–180
- Steinkasserer A, Estaller C, Weiss E H, Sim R B, Day A J. Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein-I. Biochem J 1991; 277: 387–391
- Bevers E N. New insight on the mode of action of lupus anticoagulant. International workshop of β2GPI and antiphospholi-pid antibodies. Milano October 25–26, 1991
- Janoff A S. Relationship of lipid and antibody: phospholipid three dimensional structure determines antigenicity. September 25, 1991, Antiphospholipid antibodynupus Anticoagulant workshop. NIH Bethesda
- Gharavi A E, Sammaritano L R. Induction of antiphospholipid antibodies by immunization with a lipid binding protein, β2 glycoprotein. September 25, 1991, Antiphospholipid antibodynupus Anticoagulant workshop. NIH Bethesda
- Rauch J. Immunology of anti-phospholipid antibodies. Antiphospholipid antibodykupus Anticoagulant workshop. September 25, 1991, NIH Bethesda
- Valesini G. Induction of anti-β2GPI by active immunization. International workshop on β2GPI and antiphospholipid antibodies. Milano October 25–26, 1991
- Cabral R. β2GPI dependence of antiphospholipid antibodies. International workshop on β2GPI and antiphospholipid antibodies. Milano October 25–26, 1991